madman
Super Moderator
Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study
Tatiane Fernandes, MD, Adriana O. Pedro, MD, PhD, Luiz F. Baccaro, MD, PhD,
and Lucia H. Costa-Paiva, MD, PhD
CONCLUSIONS
In conclusion, these data show that 12 weeks of treatment with topical testosterone or topical estrogen in postmenopausal women with symptoms of vaginal atrophy demonstrated laboratory and endometrial safety when compared with placebo. The high prevalence of symptomatology in menopausal urogenital atrophy reinforces the need to explore alternative treatments to estrogen therapy to improve the quality of life of these women.
Tatiane Fernandes, MD, Adriana O. Pedro, MD, PhD, Luiz F. Baccaro, MD, PhD,
and Lucia H. Costa-Paiva, MD, PhD
CONCLUSIONS
In conclusion, these data show that 12 weeks of treatment with topical testosterone or topical estrogen in postmenopausal women with symptoms of vaginal atrophy demonstrated laboratory and endometrial safety when compared with placebo. The high prevalence of symptomatology in menopausal urogenital atrophy reinforces the need to explore alternative treatments to estrogen therapy to improve the quality of life of these women.
Attachments
Last edited: